What is the monthly dosage of Zolbetuximab-Vyloy?

Zolbetuximab (Zolbetuximab), trade name Vyloy, is a targeted antibody drug mainly used to treat HER2-negative gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma, especially for Claudin 18.2-positive patients. As an innovative targeted therapy drug, zotuximab targets the Claudin 18.2 protein on the surface of cancer cells and synergizes with chemotherapy drugs to exert anti-tumor effects. Due to its unique therapeutic mechanism, the dosage and dosing regimen of zotuximab are often important considerations during patient treatment.

As for the dosage of zotuximab, the first thing to make clear is that this drug is usually used in combination with other chemotherapy drugs, especially fluoropyrimidine- and platinum-based chemotherapy drugs. The core of the treatment plan is to adjust the drug dosage according to the patient's body surface area. According to Vyloy's clinical medication guidelines, the recommended dose of zotuximab is: the initial intravenous injection dose is 800 mg/m² (800 mg per square meter of body surface area), and subsequent doses are 600 mg/m² intravenously every 3 weeks, or 400 mg/m² every 2 weeks. The specific dosage frequency is determined according to the patient's specific treatment situation and the doctor's judgment.

Thus, during a one-month treatment cycle, patients typically receive two or three doses, depending on the frequency recommended by their doctor. If the patient chooses to administer the drug every 2 weeks, he or she will need two intravenous injections of 400 mg/m² each time in a month; if the patient chooses to take the drug every 3 weeks, he or she will need one intravenous injection of 600 mg/m² each time in a month.

When taking zotuximab, patients also need to be combined with other treatments, such as antiemetic drugs, to prevent treatment-induced nausea and vomiting symptoms. During the administration of zotuximab, especially during the first administration, some allergic reactions or infusion-related reactions may occur. Therefore, pretreatment is usually required before treatment to reduce the incidence of adverse reactions.

Reference: https://en.wikipedia.org/wiki/Zolbetuximab